Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COMT | P21964 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.38 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | TYR | P14679 | 2/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28503026 | 0.91 | COMT (0.40) | COMTMAPK14GSTP1GRM2TYR | |
| SCHEMBL28905755 | 0.90 | COMT (0.40) | COMTMAPK14GSTP1TYRNPC1 | |
| SCHEMBL28501964 | 0.88 | COMT (0.39) | COMTMAPK14GSTP1GRM2NPC1 | |
| SCHEMBL20540620 | 0.87 | COMT (0.40) | COMTMAPK14GSTP1TYRLTA4H | |
| SCHEMBL20540640 | 0.87 | COMT (0.40) | COMTMAPK14GSTP1 | |
| SCHEMBL28513996 | 0.87 | COMT (0.38) | COMTMAPK14TYR | |
| SCHEMBL28905753 | 0.85 | TYR (0.41) | COMTMAPK14TYR | |
| SCHEMBL28501968 | 0.84 | COMT (0.45) | COMTMAPK14GSTP1NPC1CYP1A2 | |
| SCHEMBL28507869 | 0.84 | COMT (0.45) | COMTMAPK14GSTP1LTA4H | |
| SCHEMBL28505153 | 0.84 | TYR (0.42) | COMTTYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112062713-B | ALA-HPO hybrid derivative with iron chelation and PDT activity and preparation method and application thereof | 浙江工业大学 | 2023-03-31 | — | — | CN | disclosed |
| EP-3380471-B1 | TETRAHYDRO-8H-PYRIDO[1,2-A]PYRAZINE-8-ONES AS COMT INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | LIEBER INST INC DBA LIEBER INST FOR BRAIN DEVELOPMENT (US) | 2021-09-08 | — | — | EP | disclosed |
| US-20210139479-A1 | COMT Inhibiting Methods and Compositions | LIEBER INST INC (US) | 2021-05-13 | — | — | US | disclosed |
| US-20210139479-A1 | COMT Inhibiting Methods and Compositions | LIEBER INST INC (US) | 2021-05-13 | — | — | US | disclosed |
| US-10934283-B2 | COMT inhibiting methods and compositions | LIEBER INSTITUTE, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10934283-B2 | COMT inhibiting methods and compositions | LIEBER INSTITUTE, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| CN-112062713-A | ALA-HPO hybrid derivative with iron chelation and PDT activity and preparation method and application thereof | 浙江工业大学 | 2020-12-11 | — | — | CN | disclosed |
| US-20180305354-A1 | COMT Inhibiting Methods and Compositions | LIEBER INSTITUTE, INC. | 2018-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180305354-A1 | COMT Inhibiting Methods and Compositions | COMT, MAOB, MAOA | COMT 1/4885MAPK14 3441/4885GSTP1 90/4885 |
| US-20210139479-A1 | COMT Inhibiting Methods and Compositions | COMT, PNMT, HNMT | COMT 1/4885MAPK14 3582/4885GSTP1 81/4885 |
| US-10934283-B2 | COMT inhibiting methods and compositions | COMT, MAOB, MAOA | COMT 1/4885MAPK14 3441/4885GSTP1 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.